Anca Askanase, MD, MPH
Associate Professor of Medicine
Director, Lupus Center
Columbia University Medical Center
New York-Presbyterian Hospital
New York, NY
This activity targets healthcare gaps related to the identification and understanding of potential therapeutic targets for treating systemic lupus erythematous (SLE), impacting SLE management and potential utilization of targeted treatment.
- By addressing these gaps, you can assess whether your treatment approaches to SLE include considering the use of biologic agents in addition to corticosteroids and immunosuppressants, allowing modifications of treatment approaches to help close these gaps.
- Expert discussion will guide you in identifying potential pathophysiologic targets, deciding whether treatment with biologic agents is indicated, and utilizing clinical trial data and algorithms to guide treatment approaches based on disease severity.
- You will also be immersed in dynamic animations utilizing a whiteboard platform to memorably highlight key points related to disease pathophysiology as it relates to the role of interferons and biologic agents targeting the interferon alpha receptor.
Please note that this program was recorded before voclosporin was FDA-approved on January 22, 2021.
Voclosporin is now approved for use in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis. This approval was based on data from the phase 3 AURORA study and phase 2 AURA-LV study, which together demonstrated significant outcome improvements up to 52 weeks when voclosporin was added to typical standard of care (SoC), mycophenolate mofetil and low-dose steroids as compared with SoC alone.
This activity is designed to meet the educational needs of U.S.-based rheumatologists and other healthcare professionals involved in the management of patients with SLE. We aim to educate and offer multiple resources to more than 3000 of the targeted practitioners.
After completing the CME activity, learners should be better able to:
- Examine the roles of IFNs in the pathophysiology of SLE and how new findings can inform potential therapeutic targets;
- Identify the mechanisms of action of FDA-approved and emerging biological treatment options for patients with SLE; and
- Discuss challenges in developing novel biologic therapies for SLE owing to a lack of clearly defined clinical trial efficacy endpoints.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group will designate this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with systemic lupus erythematosus.
Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Askanase has disclosed that she served on the speakers bureau, served as an investigator, and consultant for AbbVie, Amgen, AstraZeneca, Aurinia, BMS, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, Pfizer, and UCB.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form to Med Learning Group.
Upon completion, you will receive your certification as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
RELEASE DATE: December 17, 2020
EXPIRATION DATE: December 17, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.
AMERICANS WITH DISABILITY ACT
MLG will be glad to assist you with any special needs. Please contact Med Learning Group prior to the online event at firstname.lastname@example.org.
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.